Obecabatagene autoleucel

A CAR T-cell therapy developed by UCLB spinout, Autolus Therapeutics, shows early promise as a new treatment option for people living with severe, treatment-resistant lupus. The early findings, presented at the EULAR European Congress of Rheumatology, come from the ongoing Phase I CARLYSLE study led by UCL and UCLH. The trial is evaluating obe-cel (obecabtagene autoleucel) in patients with severe refractory systemic lupus erythematosus (SLE). Initial data indicates a favourable safety profile and encouraging signs of clinical benefit. Patient Katie Tinkler receives experimental CAR T-cell therapy for lupus at University College London Hospital. November 2024 (Credit: Lucy North/PA Wire) Addressing a significant unmet need Lupus is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissue; this causes inflammation and damage across multiple organs, including the kidneys, lungs and heart. It affects at least five million people worldwide, around 90% of whom are women. For people with refractory lupus, standard treatments do not adequately control the disease, leaving them with limited treatment options and an ongoing risk of serious complications. The CARLYSLE study is exploring whether CAR T-cell therapy, an approach already transforming outcomes in certain blood cancers, could help reset the immune system in autoimmune disease. CAR T-cell therapy works by reprogramming a patient’s own immune cells so they can recognise and target specific cells in the body. It has already been approved for use in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL), including recent NHS use in England. Its evaluation in CARLYSLE is a potential extension of this UCL-derived technology from cancer into severe autoimmune disease. Katie Tinkler’s lupus was put into remission after receiving breakthrough CAR T-cell treatment at UCLH (Credit: Lucy North/PA Wire) Exploring an immune reset In lupus, obe-cel – that is, reprogrammed T-cells – is being investigated for its ability to target CD19-positive B cells, which play an important role in driving the disease and attacking normal tissue. By depleting these cells, including antibody-producing plasmablasts, the therapy aims to interrupt the autoimmune process that causes the damage, rather than suppressing the entire immune system. The trial enrolled patients aged 12 to 65 with active, severe SLE who had not responded to multiple previous treatments. Participants received a single infusion of obe-cel following lymphodepletion, at one of two dose levels. As of November 2025, nine adult patients had been treated. All had highly active disease at baseline, with most affected by lupus nephritis, a serious kidney complication of lupus. Katie Tinkler, 52, who had lived with lupus for decades, was among the trail participants. She was running out of treatment options as the disease affected her kidneys, lungs and heart. “I literally couldn’t walk from Warren Street tube station to the outpatient department without stopping. My joints were so painful that it was prohibiting me from living my life, and it was only getting worse. My whole system was affected,” she said. “Life was very hard work, and that was 24/7.” When doctors at UCLH offered her the opportunity to join the CARLYSLE trial, Katie knew the treatment carried significant risks. After undergoing the therapy from doctors at UCLH, her symptoms improved within weeks, her disease markers returned to normal for the first time in over 30 years, and she has since returned to everyday activities, from swimming and gardening to dancing at her daughter’s wedding. Katie had treatment in November 2024 and is still well – her lupus is in remission. She no longer needs medication and her organs have recovered. (Credit: UCLH) “I can participate in life now whereas before I had to watch my family and friends doing physical activities from the sidelines,” she said. “At my daughter’s wedding I danced all night. The summer before, I wouldn’t have been able to do that.” Dr. Richard Fagan, Director of BioPharm at UCLB, said: “These early findings are an encouraging indication of the wider potential of UCL science to change the lives of patients with serious, treatment-resistant conditions. Autolus is a strong example of how long-term academic innovation, combined with the right commercial support, can create technologies with the potential to move from breakthrough discovery to real-world patient impact.” Encouraging early safety and efficacy signals One of the most notable findings so far is the therapy’s safety profile. Researchers observed no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) and no moderate or severe cytokine release syndrome (CRS), both known risks associated with CAR T-cell therapies. There was one dose-limiting toxicity involving liver injury, which fully resolved. Other side effects, such as neutropenia and infections, were considered manageable and consistent with expectations for this type of treatment. Alongside these safety signals, early signs of clinical benefit were seen. In the lower dose group, five out of six patients achieved remission according to standard lupus criteria, with improvements emerging within months of treatment. Patients showed rapid reductions in disease activity scores, anti double stranded DNA antibodies and improvements in complement levels. Patients with kidney involvement also demonstrated encouraging responses, including reductions in proteinuria and stabilisation or improvement of kidney function. From UCL research to patient impact Following treatment, patients experienced deep depletion of B cells and robust CAR T-cell expansion. As B cells returned, typically after three to six months, they were predominantly early-stage cells rather than the mature populations associated with autoimmune activity, suggesting a genuine immune “reset”. The therapy used in this study, known as AUTO1/obe cel, was developed at UCL by a team led by Professor Martin Pule for blood cancers. The work builds on more than two decades of UCL research into immune cell targeting and underlines the long-term value of academic discovery translated into clinical innovation. If confirmed in larger trials, obe-cel could represent a new treatment paradigm for people with severe, treatment resistant lupus, and a powerful example of how UCL derived science – supported through UCLB’s commercial translation – can deliver meaningful impact for patients. UCLB’s journey with  Autolus NASDAQ-listed Autolus Therapeutics is an early-commercial stage biopharmaceutical company developing next-generation programmed T-cell therapies. Beginning its journey with Proof of Concept funding, UCLB’s support also included facilitating the spinout process, managing intellectual property, and fostering partnerships. The company has raised over $1.1bn of investment capital since incorporation, employing more than 450 people, and opening a state-of-the-art production facility, The Nucleus in Stevenage. The foundational research underpinning obe-cel was conducted at UCL and led by Dr. Martin Pule and his collaborators at the UCL Cancer Institute and Great Ormond Street Institute of Child Health. UCLB and Autolus entered into a licence agreement for patent rights relating to obe-cel back in 2018. If you’re a UCL researcher interested in exploring how to turn your research into impact, contact us for a confidential, no-obligation chat – whatever stage your research is at.

AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of success and expected commercialization timelines into measurable balance sheet value. Companies at the forefront of this shift, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are actively leveraging this evolving framework. Operating at the intersection of oncology therapeutics and AI-driven drug development, Oncotelic demonstrates how scientific advancement can influence financial positioning. Through a diversified pipeline and strategic holdings, including a 45% interest in GMP Bio, which was recently assessed at more than $1 billion in enterprise value, the company illustrates how innovation can be reflected in tangible economic terms. As the industry increasingly aligns valuation with development progress rather than current revenue, Oncotelic represents a compelling example of science emerging as a recognized asset class. The company is part of a broader group of organizations developing advanced therapies at the genetic and molecular level, including Autolus Therapeutics plc (NASDAQ: AUTL), Wave Life Sciences Ltd. (NASDAQ: WVE), IO Biotech Inc. (OTC: IOBTQ) and Roche Holding AG (OTC: RHHBY). The biotech sector is transitioning away from a framework dominated by long-term research spending toward one in which scientific progress can be directly reflected in financial valuation.As drug candidates progress through the stages of clinical development, their value tends to rise substantially due to increasing probabilities of success and closer proximity to commercialization.Oncotelic Therapeutics provides a clear example of the growing adoption of fair-value accounting through the remeasurement of its stake in GMP Bio.Based on this evolving investment landscape, Oncotelic Therapeutics is situated to benefit from increasing institutional interest in pipeline-driven valuation.The company operates within this key convergence by combining oncology-focused development with AI-enabled platforms and exposure to manufacturing capabilities. Click here to view the custom infographic of the Oncotelic Therapeutics editorial. Scientific Advancement Emerging as Measurable Value The biotech sector is transitioning away from a framework dominated by long-term research spending toward one in which scientific progress can be directly reflected in financial valuation. Traditionally, investors relied heavily on discounted cash-flow models tied to eventual commercialization outcomes, which often created a disconnect between innovation and perceived value. With the growing adoption of fair-value accounting methodologies under U.S. GAAP, that gap is beginning to close as companies gain the ability to adjust asset valuations in response to clinical and regulatory progress. Under guidance from the Financial Accounting Standards Board, particularly ASC 820, companies can determine the fair value of assets, including early-stage or illiquid investments, using a combination of observable and unobservable inputs. This includes Level 3 classifications, which are frequently applied in biotechnology to assess the value of pipeline programs and strategic holdings. These valuation approaches allow organizations to incorporate factors such as clinical advancement, regulatory status and probability of success into financial reporting. Leading advisory firms have emphasized that valuation in the life sciences sector increasingly depends on forward-looking inputs, including development progress and anticipated commercialization potential. Because fair-value accounting requires assets to be measured from the perspective of market participants, these frameworks inherently incorporate expectations about future economic benefit. As a result, financial reporting becomes more closely aligned with the operational realities of drug development, where revenue generation often lags innovation. This evolving approach is particularly relevant for Oncotelic Therapeutics, whose value is closely tied to the advancement of its therapeutic pipeline. By aligning financial reporting with clinical and strategic milestones, the company reflects a broader industry shift toward recognizing scientific progress as a core driver of enterprise value. Advancing Pipelines and Valuation Acceleration As drug candidates progress through the stages of clinical development, their value tends to rise substantially due to increasing probabilities of success and closer proximity to commercialization. This progression, often described as a valuation inflection point, is widely observed across the biotechnology landscape. Assets in late-stage development, particularly those nearing regulatory approval, frequently represent a disproportionate share of overall company value. Research from McKinsey & Company indicates that value creation within biopharma is heavily concentrated in later-stage programs, where reduced uncertainty and clearer pathways to market translate into stronger expected returns. Additional industry analysis supports the view that assets approaching commercialization often drive significant increases in valuation due to improved probability-adjusted outcomes and anticipated market entry. This trend underscores a broader shift in how investors evaluate biotechnology companies. Rather than concentrating primarily on existing revenue or earnings, attention is increasingly directed toward the maturity and forward trajectory of pipeline assets. Consequently, companies with advanced-stage programs may experience meaningful increases in valuation even prior to generating commercial revenue. For Oncotelic Therapeutics, this dynamic is applicable given its focus on oncology therapies and its positioning within high-value development pathways. As the company’s pipeline advances toward later stages, its valuation profile aligns with the broader industry movement toward pipeline-driven value recognition. Fair-Value Frameworks Gain Momentum in Biotech The growing adoption of fair-value accounting within biotechnology is supporting more accurate and timely representation of asset value. Under GAAP, Level 3 valuation methodologies are applied to assets without observable market prices, using models that rely on forward-looking assumptions such as expected cash flows and probability-weighted scenarios. The ASC 820 framework describes fair value as the price that would be received in an orderly transaction between market participants at the measurement date. It establishes an organized hierarchy for valuing complex or illiquid assets using the best available information and market-based assumptions. This approach ensures that financial reporting reflects a current and economically relevant view of asset value. Oncotelic Therapeutics provides a clear example of this methodology through the remeasurement of its stake in GMP Bio, which reflects an enterprise valuation exceeding $1 billion. This shows how clinical advancement and strategic positioning can translate into measurable balance sheet strength, reinforcing the concept that scientific progress carries financial significance. Institutional Investors Embrace Prerevenue Opportunities Institutional investors are acknowledging the value of clinical-stage biotechnology assets, even in the absence of current revenue. This swing indicates increasing confidence in structured valuation approaches that encompass scientific progress instead of only on traditional financial metrics. In many cases, biotech companies are assessed based mostly on the strength of their development pipelines rather than current income streams. Given the extended timelines required to bring therapies to market, valuation is often driven by factors such as clinical stage, probability of success and regulatory milestones. This framework highlights that value creation in the sector frequently occurs well before commercialization, as investors rely on milestone-based and probability-adjusted methodologies to assess future potential. Based on this evolving investment landscape, Oncotelic Therapeutics is situated to benefit from increasing institutional interest in pipeline-driven valuation. The companys varied assets and strategic investments align with the kinds of opportunities that are attracting capital across the biotechnology sector. Integration of AI, Manufacturing and Market Readiness Technological advancements in artificial intelligence and GMP-compliant manufacturing are fast-tracking development timelines while enhancing scalability throughout the biotechnology sector. These innovations support increasingly efficient clinical workflows, improved data analysis and streamlined production procedures, ultimately decreasing development time and cost. Artificial intelligence is playing a greater role in identifying therapeutic targets, optimizing clinical trial design and analyzing complex datasets. These capabilities improve the likelihood of success in drug-development programs. In addition, advancements in GMP-compliant manufacturing are supporting more consistent and scalable production, which becomes critical as therapies move closer to commercialization. Industry research suggests that data-driven methods are becoming central to value creation in biopharma, with AI and advanced analytics contributing to faster development timelines and improved execution. The intersection of technology, manufacturing and clinical development is redefining how value is generated and assessed within the sector. Companies capable of integrating these capabilities are better positioned to advance therapies efficiently while maintaining regulatory compliance. Oncotelic Therapeutics operates within this convergence by combining oncology-focused development with AI-enabled platforms and exposure to manufacturing capabilities. This cohesive strategy encourages both innovation and financial valuation, placing the company in a key biotech growth trend. The biotechnology industry is seeing a new chapter in which scientific advancement is increasingly recognized as a measurable financial asset rather than mainly a cost center. As fair-value accounting, pipeline maturity and AI-fueled development continue to redefine the sector, the conventional divide between innovation and valuation is decreasing. Savvy companies such as Oncotelic Therapeutics demonstrate how this change is taking place in practice, showing that clinical progress can strengthen financial positioning even prior to revenue generation. As investor focus continues to shift toward pipeline-driven value, the ability to convert scientific progress into measurable economic impact is becoming a defining feature of modern biotechnology. Biotech Advances Drive Valuation Momentum Biotechnology advancements remain central to how companies are valued, as clinical progress, regulatory milestones and platform innovations often serve as key inflection points for both therapeutic development and investor perception. As drug candidates move through trials and toward commercialization, each update can reshape expectations around risk, scalability and long-term revenue potential, reinforcing the close link between scientific progress and market valuation. Autolus Therapeutics plc (NASDAQ: AUTL) is reporting continued progress across its platform, noting that it is developing, manufacturing and delivering next-generation programmed T cell therapies. In its Q4 and FY2025 update, the company noted a strong first year of launch of AUCATZYL in the U.S., building a market-leading position in adult patients with relapsed or refractory B-ALL and demonstrating strong commercial execution, including reliable, high-quality product delivery with consistent turn-around time. Wave Life Sciences Ltd. (NASDAQ: WVE) noted new 2026 developments centered on its RNA-based therapeutics pipeline, including progress in obesity and genetic disease programs. In its latest update, the company emphasized that it is focused on unlocking the broad potential of RNA medicines to transform human health. The announcement underscored advancing clinical trials and expanding applications of RNA editing and RNA interference technologies, reinforcing the growing role of precision genetic medicine in addressing both rare and common diseases. IO Biotech Inc. (OTC: IOBTQ) announced a strategic shift in 2026 as it evaluates future pathways to maximize value. The company is developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. IO Biotech has a T-win platform based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. Roche Holding AG (OTC: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Gazyva(R)/Gazyvaro(R) (obinutuzumab) for the treatment of systemic lupus erythematosus (SLE). The acceptance is based on positive results from the phase III ALLEGORY study, which demonstrated a statistically significant and clinically meaningful benefit in the primary endpoint of SLE Responder Index 4 (SRI-4) at 52 weeks, a measure that assesses changes in disease severity, symptoms and physical condition. These updates reflect a biotechnology sector defined by rapid scientific innovation, platform diversification and increasingly complex development pathways. From cell therapies and RNA-based medicines to immuno-oncology and neurodegenerative research, progress across multiple fronts continues to shape both therapeutic potential and market expectations. As companies advance through clinical milestones and refine their strategic direction, the interplay between innovation and valuation remains a defining feature of the biotech landscape. For more information, visit Oncotelic Therapeutics Inc. About BioMedWire BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.comBioMedWire is powered by IBN